Benjamin Enerson
Conseiller Juridique Général chez THESEUS PHARMACEUTICALS, INC.
Profil
Benjamin Enerson is currently working as Vice President-Legal Affairs at Theseus Pharmaceuticals, Inc. Prior to this, he worked as General Counsel at Finch Therapeutics Group, Inc. and Tremeau Pharmaceuticals, Inc. He completed his undergraduate degree from Vanderbilt University and his graduate degree from Cornell Law School in 2004.
Postes actifs de Benjamin Enerson
| Sociétés | Poste | Début |
|---|---|---|
| THESEUS PHARMACEUTICALS, INC. | Conseiller Juridique Général | - |
Anciens postes connus de Benjamin Enerson
| Sociétés | Poste | Fin |
|---|---|---|
| FINCH THERAPEUTICS GROUP, INC. | Conseiller Juridique Général | - |
Tremeau Pharmaceuticals, Inc.
 Tremeau Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tremeau Pharmaceuticals, Inc. engages in the developing and delivering of non-opioid pain therapies. The firm product includes TRM-201 (rofecoxib). The company was founded by Bradford C. Sippy and Mark H. N. Corrigan in 2016 and is headquartered in Concord, MA. | Conseiller Juridique Général | - |
Formation de Benjamin Enerson
| Cornell Law School | Graduate Degree |
| Vanderbilt University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| FINCH THERAPEUTICS GROUP, INC. | Health Services |
| Entreprise privées | 2 |
|---|---|
Theseus Pharmaceuticals, Inc.
 Theseus Pharmaceuticals, Inc. BiotechnologyHealth Technology Theseus Pharmaceuticals, Inc. engages in the development of pan-variant kinase inhibitors. It focuses on the discovery, development and commercialization of transformative targeted therapies. The company was founded by William C. Shakespeare, David C. Dalgarno, Iain D. Dukes, Wei Sheng Huang and Victor M. Rivera on December 29, 2017 and is headquartered in Cambridge, MA. | Health Technology |
Tremeau Pharmaceuticals, Inc.
Tremeau Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tremeau Pharmaceuticals, Inc. engages in the developing and delivering of non-opioid pain therapies. The firm product includes TRM-201 (rofecoxib). The company was founded by Bradford C. Sippy and Mark H. N. Corrigan in 2016 and is headquartered in Concord, MA. | Health Technology |